FDA Policy In Biosimilars, “Breakthrough” And Social Media Under New Management
This article was originally published in The Pink Sheet Daily
Office of Medical Policy’s leadership gets reshuffled following retirement of the long-time CDER denizen Rachel Sherman.
You may also be interested in...
Chief Scientist At US FDA Is Hinton As Borio Moves To White House
Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.
FDA Drug Policy Office Director Candidate Getting Four-Month Tryout
OHOP’s Jonathan Jarow will serve 120-day detail as acting director of CDER’s Office of Medical Policy before FDA makes final decision on permanent head of the office.
Former FDA Medical Policy Head Joins Greenleaf, Will Highlight FDA As “Resource”
Rachel Sherman to expand drug capacity at FDA-centered consultancy, following 25 years at agency.